![Page Image](https://mumcdnstorage.blob.core.windows.net/dwnews/2023/10/Lung-Cancers-Today_Site_Box_Banner_800x800.png)
Non-Small Cell Lung Cancer
The trial is the first to evaluate the investigational telomere-targeting agent with a PD-(L)1 inhibitior.
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
A researcher discusses the implications of identifying potentially pathogenic bacteria in adenocarcinoma tumors.
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
Valsamo Anagnostou, MD, PhD, discusses advances in the field and her lab's research on the topic.
The drug combination showed "reduced efficacy" in terms of PFS and OS, officials said.
IDE397, a “potential first-in-class” MAT2A inhibitor, is under evaluation in phase 2 clinical trials.
Advertisement
Expert Interviews on Lung Cancer
Advertisement